1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPHS 2023 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications is sponsored by National Institutes of Health (NIH). Supports small businesses in collaboration with research institutions to develop health-related technologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-OD-22-101: Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2022-2 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2022-2 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications Estimated Publication Date of Funding Opportunity Announcement: First Estimated Application Due Date: Earliest Estimated Award Date: Earliest Estimated Start Date: PA-21-259 - PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PA-21-260 - PHS 2021-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) PA-21-262 - PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) PA-21-261 - PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) Office of The Director, National Institutes of Health ( OD ) This Notice is to inform the eligible United States small business concerns of the reissuance of the Omnibus Solicitations of the NIH, CDC and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.
When reissued, these FOAs will continue to utilize the R41/R42 and R43/44 grant mechanisms. Modifications to these FOAs will be the inclusion of new and revised research priorities.
NIH, CDC, and FDA Institutes and Centers likely to participate in one or more of the FOAs include the following: National Institutes of Health (NIH) National Cancer Institute ( NCI ) National Eye Institute ( NEI ) National Heart, Lung, and Blood Institute ( NHLBI ) National Human Genome Research Institute ( NHGRI ) National Institute on Aging ( NIA ) National Institute on Alcohol Abuse and Alcoholism ( NIAAA ) National Institute of Allergy and Infectious Diseases ( NIAID ) National Institute of Arthritis and Musculoskeletal and Skin Diseases ( NIAMS ) National Institute of Biomedical Imaging and Bioengineering ( NIBIB ) Eunice Kennedy Shriver National Institute of Child Health and Human Development ( NICHD ) National Institute on Deafness and Other Communication Disorders ( NIDCD ) National Institute of Dental and Craniofacial Research ( NIDCR ) National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ) National Institute on Drug Abuse ( NIDA ) National Institute of Environmental Health Sciences ( NIEHS ) National Institute of General Medical Sciences ( NIGMS ) National Institute of Mental Health ( NIMH ) National Institute of Neurological Disorders and Stroke ( NINDS ) National Institute of Nursing Research ( NINR ) National Institute on Minority Health and Health Disparities ( NIMHD ) National Library of Medicine ( NLM ) National Center for Complementary and Integrative Health ( NCCIH ) National Center for Advancing Translational Sciences ( NCATS ) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs ( ORIP ) Centers for Disease Control (CDC) Center for Global Health ( CGH/CDC ) National Center on Birth Defects and Developmental Disabilities ( NCBDDD/CDC ) National Center for Chronic Disease Prevention and Health Promotion ( NCCDPHP/CDC ) National Center for Emerging and Zoonotic Infectious Diseases ( NCEZID/CDC ) National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention ( NCHHSTP/CDC ) National Center for Immunization and Respiratory Diseases ( NCIRD/CDC ) National Center for Injury Prevention and Control ( NCIPC/CDC ) National Institute for Occupational Safety and Health ( NIOSH/CDC ) National Center for Environmental Health ( NCEH/CDC ) Center for Preparedness and Response ( CPR/CDC ) Food and Drug Administration (FDA) Center for Biologics Evaluation and Research ( CBER/FDA ) Center for Drug Evaluation and Research ( CDER/FDA ) Center for Food Safety and Applied Nutrition ( CFSAN/FDA ) Center for Devices and Radiological Health ( CDRH/FDA ) Center for Veterinary Medicine ( CVM/FDA ) Office of Critical Path Programs ( CPI/FDA ) Office of Orphan Products Development ( OOPD/FDA ) This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.
The FOA is expected to be published in Summer 2022 with an expected application due date in September 2022.
Research Initiative Details The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.
The STTR program is intended to stimulate a partnership of ideas and technologies between innovative small business concerns and non-profit research institutions through Federally-funded research or research and development (R/R&D).
By providing awards to small businesses for cooperative R/R&D efforts with non-profit research institutions, the STTR program assists the small business and research communities by commercializing innovative technologies. SBIR/STTR are phased programs.
The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts, whereas in SBIR/STTR Phase II it is to continue the R&D efforts to advance the technology toward ultimate commercialization. An objective of the SBIR and STTR programs is to increase private sector commercialization of innovations derived from federally supported research and development.
At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal). Diversity within the NIH-supported scientific workforce fosters innovation, enhances global competitiveness, improves the quality of research and research outcomes.
NIH has a commitment to supporting a sustainable and diverse biomedical research workforce. (Notice of NIH's Interest in Diversity, NOT-OD-20-031 ) . Scientists and trainees from underrepresented backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems.
Fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses in technological innovation is one of the goals of the SBIR and STTR programs. ( https://www. sbir.
gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.
pdf ) NIH intends to re-issue the four Funding Opportunity Announcements (FOAs): Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) Expected Number of Awards Primary Assistance Listing Number(s) Anticipated Eligible Organizations Applications are not being solicited at this time.
Please direct all inquiries to: SEED (Small business Education and Entrepreneurial Development) Office of Extramural Research Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Small businesses collaborating with research institutions on health technology development. Confirm the full requirements in the official notice before applying.
PHS 2023 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article